OptiBiotix Health PLC Director Appointment (1750A)
September 10 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 1750A
OptiBiotix Health PLC
10 September 2018
OptiBiotix Health plc
("OptiBiotix")
Director Appointment
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, announces that, further to the
previous announcement made on 6 August 2018 regarding the proposed
appointment of Sean Christie as Non-Executive Director of the
Company, the regulatory due diligence process has now been
completed and the text below sets out the required disclosures.
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies, the following information is disclosed in respect of
Michael Sean Christie (aged 60):
Current Appointments Appointments in the last
5 years
ACCSYS Technologies Plc Croda Enterprises Limited
Applied Graphene Materials Croda Europe Limited
Plc
Turner & Townsend Limited Croda International Plc
Croda Investments Limited
Croda Investments No 2 Limited
Croda JDH Limited
Croda Overseas Holdings
Limited
Croda Polymers International
Limited
Croda World Traders Limited
Eminate Limited
Produce Investments Limited
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Lianne Cawthorne Mob: 07584 391 303
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGURGBUPRGCM
(END) Dow Jones Newswires
September 10, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024